

Better Antibodies By Design

Investor Presentation December 2015





Forward Looking Statement

This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably gualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation.

Antibody Innovation Generating World Class Products



Focus on Cancer

- Differentiated human antibodies
- Track record breakthrough therapeutics

a series	and a constant of the same					
	-		-		-	~~~
Dramit grapharyfit Bostama (fill)		_	_	_	_	-
alayar yearana (%)	-	_	_	_	-	
Music large & call (crightenia (186.01)		_	_	_		
Antiputation configurate (PAC)	-	_	_	_	-	
helepung nendling multiple actions (MMMT))		_	_			
Contractor in the contractor (1997)	-	_	_	-		
National Providence (1997)	-	_	_	_	-	
Nation Dyroid ago disease		_	-	-		
table servers	-					
villate, Echamoral Nutrate, Multiste-ADE, effectly at Daublinky-ADE	-					

Robust Product Pipeline

- Daratumumab blockbuster potential (marketed as Darzalex[™] in MM)
- Ofatumumab cancer & autoimmune potential (marketed as Arzerra® in various CLL indications)
- HuMax[®]-TF-ADC in Phase I solid cancers



Passion for Innovation

- World class antibody know-how
- Proprietary technologies DuoBody[®] & HexaBody[™]
- Innovative pre-clinical pipeline



$\mathsf{Partnerships} \to \mathsf{Product}\ \mathsf{Ownership}$

- Key collaborations drive current pipeline
- Product opt-ins + retain products for future value
- Well capitalized



Innovative Pipeline Further Development for Marketed Products

			Develop	ment Phase	
Product	Disease Indications	Pre- clinical	1	II	ш
Daratumumab Target: CD38	Multiple myeloma (MM)				
Partner: Janssen	Non-Hodgkin's lymphoma (NHL)				
Ofatumumab Target: CD20 Indication:	Chronic lymphocytic leukemia (CLL)				
Cancer Partner: Novartis	Follicular lymphoma (FL)				
Ofatumumab Target: CD20	Pemphigus vulgaris (PV) (SubQ)				
Indication: AI Partner: GSK	Relapsing remitting multiple sclerosis (RRMS) (SubQ)		Ann	ounced	
(transfer to Novartis)	Neuromyelitis optica (NMO) (SubQ)		Announ	ced	



Genmab **Innovative Pipeline Continued Antibody Powerhouse**

			Develop	ment Phase	
Product	Disease Indications	Pre- clinical	I	Ш	Ш
HuMax-TF-ADC Target: TF Partner: Seattle Genetics	Solid Cancers			•	
Teprotumumab Target: IGF-1R	Graves' Orbitopathy				
Partner: River Vision	Diabetic macular edema			•	
HuMax-TAC-ADC Target: CD25	Lymphoma		\rightarrow	•	
Partner: ADCT	Acute myeloid leukemia (AML)	Anno	ounced		
HuMax-IL8 Target: IL-8 Partner: Cormorant	Metastatic solid tumors				
EGFR x cMet (JJ372) Target: EGFR Partner: Janssen	Non-small-cell lung cancer (NSCLC)	Anno	ounced	•	
> 30 Active Pre-clinical	Partnered programs: HuMab, DuoBody & HexaBody				
programs incl. HuMax-AXL-ADC	Proprietary programs: HuMab, HuMab-ADC, DuoBody, DuoBody-ADC & HexaBody				



DarzalexTM (daratumumab) First-in-Class Antibody with Broad-Spectrum Killing Activity

Additional Potential Blood Cancer Indications

• DLBCL, FL, Plasma Cell Leukemia, Mantle Cell Lymphoma, CLL, ALL, AML

aution: New

sponsored by J

First-in-Class Fully Human Antibody

- Targets CD38 five ways of attacking cancer cells
- Multiple Myeloma & other blood cancers
- Blockbuster potential
- Promising clinical data, broad & expansive development in MM
- Breakthrough Therapy Designation

Partner: Janssen Biotech

- Janssen funds development & commercialization
- > \$1.1B potential deal value, + double-digit royalties
- Zero cost / limited financial risk for Genmab
- Approved by the FDA, November 2015
- MAA filed with EMA, September 2015, accelerated assessment granted

Genmab

Expansive Daratumumab Clinical Development

Indiantian	dication Disease Stage Therapy		No.		Develop	ment Phase	
Indication	Disease Stage	Therapy	Pts*	I	I/II	II	III
		Dara + VMP	700		MMY300	7 (Alcyone	
	Front line (transplant & non-transplant)	Dara + Revlimid + Dex	730		MMY30)08 (Maia)	
		Dara + VTD	1,080		MMY3006	(Cassiope	ia)
*		Multi combo: 1 Study (6 arms)	190	MMY10	001 (Equul	eus)	
eloma*	* Wultiple Wyeloma Relapsed or Refractory	Dara + Revlimid + Dex	45		GEN503		
le Mye		Dara + Revlimid + Dex	570		MMY30	03 (Pollux)	
Multip		Dara + Velcade + Dex	480		MMY30	04 (Castor)	
_		Dara +Vel+Dex, Japan	6	MMY1	005		
		Mono, Japan	9	MMY1	02		
		Mono, safety	104	GE	EN501		
		Subcutaneous	128	MMY1	04		

*Approx. no. based on clinicaltrials.gov **Maintenance integrated into some study protocols

VMP = bortezomib & melphalan-prednisone VTD = bortezomib, thalidomide & dexamethasone BTD = Breakthrough Therapy Designation



Expansive Daratumumab Clinical Development Additional Indications

	Disease	No.			Developr	nent Phas	е
Indication	Stage Therapy Pts'		Pts*	I	I/II	II	ш
/eloma**	High Risk Smoldering	Mono	120	SMM	12001 (Cer	ntaurus)	
Multiple Myeloma**	Double Refractory	Mono, BTD population (Basis of US Approval, Nov 2015)	124	MI	MY2002 (S	irius)	
NHL (DLBCL / MCL / FL)	Relapsed or Refractory	Mono	210	LY	′M2001 (Ca	arina)	

*Approx. no. based on clinicaltrials.gov. **Maintenance integrated into some study protocols BTD = Breakthrough Therapy Designation




Basis for US Approval of Darzalex: Daratumumab Ph II Study Double Refractory MM

Study Design

2 part study, enrolled 124 pts Primary Objective: define Pts received at least 3 prior optimal dose, determine Part 1: defined optimal lines of therapy incl. a PI & an • efficacy of 2 daratumumab daratumumab regimen IMiD, or double refractory to treatment regimens as Part 2: expansion based on • PI & IMiD measured by ORR Part 1 Results Median prior lines of therapy: 5 Robust. durable 95% refractory to 29.2% ORR (31/106) last PI & IMiD single agent activity in 16 mg/kg dose Manageable safety group. 13 pts VGPR profile 7.4 month median 63% refractory to or better pomalidomide duration of response 48% refractory to carfilzomib


Daratumumab: Early Signs of Clinical Activity Ph I/II Revlimid Combo Study in Multiple Myeloma



- Part 1; ORR 100% (31% CR, 46% VGPR)
- Part 2; ORR 87% (7% CR, 43% VGPR)
- 75% VGPR or better in patients treated for at least 6 months

Genmab

Daratumumab: Early Signs of Clinical Activity Ph Ib MM Combo Study with Velcade / Pomalidomide Regimens



- ORR:
 - 100% in newly diagnosed group (Velcade combinations)
 - 54.5% in relapsed group –2 sCR (POM-D combination)

V, bortezomib; D, dexamethasone; DARA, daratumumab; M, melphalan; P, prednisone; T, thalidomide; POM, pomalidomide. sCR, stringent complete response; VGPR, very good partial response; PR, partial response; MR, minimal response; PD, progressive disease.

Genmab



Arzerra[®] (ofatumumab)

iili konsentraat

Ofatumumab/Ofatu

1000 mg/50 ml

Sales by GSK

- 2014 sales GBP 54.5M (~\$82.2M); royalty DKK 101M
- Genmab Cancer Royalty = 20%

Our First Marketed Product

- Human antibody targeting CD20 on cancerous B-cells
- Differentiated vs other CD20 mAb, targets slice of > \$8B market

Cancer

- Approved*
 - US 1st Line CLL in combo w/ chlorambucil
 - EU 1st Line CLL in combo w/ chlorambucil or bendamustine
- Fludarabine and alemtuzumab refractory CLL
- Phase III trials in CLL & FL
- · Partnered with Novartis
- US & EU reg. subm. for maintenance therapy relapsed CLL
 - PDUFA date: Jan. 21, 2016

Autoimmune diseases (unapproved)


- · Phase III trial ongoing in PV
- · Relapsing remitting MS Ph III's & pivotal NMO trials announced
- Current partner GSK; Aug. 2015 Novartis announced acquisition of AI rights from GSK

*In US approved in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate as well as for the treatment of patients with CLL refractory to fludarabine and alemtuzumab.

In EU approved in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabinebased therapy, as well as for the treatment of patients with CLL refractory to fludarabine and alemtuzumab.


HuMax[®]-TF-ADC: Next Generation Therapeutic Phase I in Patients with Solid Tumors

Genmab



Genmab

HuMax-TF-ADC in Patients with Solid Tumors Best Response and Duration of Follow-up





 Footnote: X denotes time of disease progression. Patients still in the trial have an "O" following the end of their bar. Dashed vertical line at 6 weeks denotes the SD-threshold, Not evaluable (because of insufficient follow-up) patients are denoted with an NE. SD: stable disease, PR: partial response.

HuMax-AXL-ADC Efficacy in *in vivo* Tumor Model

Fully Human Antibody-Drug Conjugate

- Targets AXL signaling molecule expressed on many solid cancers
- HuMax-AXL-ADC shows anti-tumor activity in patient-derived xenograft model with heterogeneous target expression
- Collaboration: Seattle Genetics







DuoBody[®] Technology Efficient & Versatile Platform for Bispecific Antibodies

DuoBody

- Dual-targeting, potential to improve specificity & efficacy
- Large scale manufacturing
- Minimal protein engineering
- Excellent quality BsAb at very high yields
- Differentiated from competitor platforms
 - Proper in vivo half-life
 - Fc-effector functions
- Good manufacturability

Ongoing Collaborations

- 5 Commercial deals
- Novartis (2 progr., \$175M potential deal value + royalties)
- Janssen Biotech (20 progr., \$3.6B potential deal value + royalties)
- Novo Nordisk (2 progr. \$250M each exclusive license / \$200M each non-exclusive license + royalties)
- BioNovion* (expansion research deal, joint development / ownership)
- BioNTech (joint development / ownership)
- 4 Research deals
- Undisclosed major Biotech, Agenus, Humabs BioMed, Pierre Fabre

*Sept 2015 Aduro BioTech, Inc. announced definitive agreement to acquire BioNovion



HexaBody[™] Technology Robust Effector Function Enhanced Antibodies

HexaBody

* HexaBody


- Enables antibodies to readily form clusters of 6 (hexamers)
- Induces & enhances target cell killing after binding via CDC
- CDC capability to essentially any antibody
- Builds on natural antibody biology minimal engineering
- Create novel, differentiated products in cancer & infect. dis.
- Repurpose / rescue drug candidates that failed in Phase II/III
- Life cycle management
- Collab. w. undiscl. major Biotech, Humabs BioMed & Agenus

Genmab's Robust Innovative Pre-Clinical Pipeline Over 30 Pre-Clinical Programs

DuoBody[™] formats *****HexaBody[™] format 100-80. 80-80-0 0 60· % viable cells 60· % lysis 60-% lysis 40-40. 40. 20-20. 20-0 0-0 0-0.001 0.01 0.1 10 0.0001 0.01 1 100 10000 0.001 0.01 0.1 1 10 Concentration Ab (µg/mL) Concentration Ab (ng/mL) Concentration Ab (µg/mL) HexaBody-X DuoBody-CD3xA **DuoBody-AxB-ADC** ----→ reference antibody (IgG1) monovalent-A-ADC+ B-ADC **-—**



Creating Value With Our Technologies






Well-Capitalized Biotech – 2015 Guidance

Income Statement	DKKM	USDM*			
Revenue	1,025 – 1,100	154 - 165			
Operating expenses	(550) – (600)	(83) – (90)			
Reversal of GSK Liability	175	26			
Operating income	625 - 700	94 - 105			
Cash position at end of year**	3,000 – 3,100	451 - 466			
*USD 1.00 = DKK 6.6588 (September 30, 2015) **Cash, cash equivalents and marketable securities					

2015 Expense Base DKK 575M (\$86M)



2015 Guidance – November 3, 2015. Revised on November 16, 2015 following the approval of Darzalex



2015 Goals: Maximizing Pipeline Value

Priority	\checkmark	Targeted Milestone
Maximize daratumumab clinical progress	✓	 » Phase II MM monotherapy data and if favorable, discuss regulatory next steps with health authorities » Start multiple new MM trials » Start non-MM clinical trial
Optimize ofatumumab value	✓ ✓ X	 » File for an additional indication » Phase III relapsed CLL data » Start Phase III sc autoimmune trials*
Strengthen differentiated product pipeline	✓ ✓ ✓	 » Phase I HuMax-TF-ADC data » Progress HuMax-AXL-ADC » Progress pre-clinical DuoBody & HexaBody projects
Broaden partnership portfolio with next generation technologies	 ✓ ✓ 	 » Expand DuoBody & HexaBody collaborations » Progress partnered programs » New IND filings
Disciplined financial management	~	» Maintain cost base while selectively investing to advance pipeline

*This milestone is not expected to be completed in 2015 due to the expected transfer of the rights for ofatumumab in autoimmune indications from GSK to Novartis.

On Track to a Sustainably Profitable Future



- Robust differentiated product pipeline
 - Daratumumab, ofatumumab, HuMax-TF-ADC
 - Innovative pre-clinical pipeline
- Proprietary technologies -DuoBody & HexaBody
- Partnerships \rightarrow Product ownership
 - Well capitalized
- Positioned for success
 - For patients & shareholders



Better Antibodies By Design

Appendix






International Shareholder Base

- Major shareholders >5%
 - FMR (Fidelity)
 - Johnson & Johnson Dev.Corp.
- ADR program in USA
 - Ticker: GMXAY
 - Sponsored level 1
 - Ratio: 2 ADR: 1 ordinary share
 - Depositary Deutsche Bank
- Shares outstanding: 59,531,263
 - Total diluted shares: 62,265,030

Geographical Shareholder Distribution December 31, 2014*





Market Sizes Estimated Prevalence in 7 Major Markets

Disease	Estimated Incidence in 7 Major Markets ¹	Estimated Prevalence	Estimated Global Branded Sales by 2018
CLL	32,000	250,000	\$5.3B
FL	32,000	260,000	\$10.5B ²
MM	55,000	190,000	\$11.5B
RRMS	26,100 ³	370,600	\$18.5B ³

¹Incidence for MS does not include Japan

²Sales data is for NHL, which includes FL

³Data is for MS, which includes RRMS

Sources: CLL, DLBCL, FL 2013 forecast incidence: Datamonitor, "Pipeline Insight: Leukemias" and "Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes", March 2010. CLL, DLBCL, FL prevalence based on median survival of 8 yrs: company estimates. MM 2012 incidence: Datamonitor, "Multiple Myeloma Epidemiology", May 2013; MM prevalence: SEER 2012; company estimates.


MS incidence, "Atlas of MS 2013"

RRMS prevalence, Datamonitor, "Multiple sclerosis Epidemiology", May 2012.

Sales data for CLL, FL, MM based on EvaluatePharma® 2014, sales data for MS from Datamonitor, "Multiple Sclerosis Forecast", 3 February 2014.



Daratumumab Induces Superior CDC



	Daratumumab (Genmab)	MOR202* ¹ (MorphoSys)	isatuximab ^{1, 2} (Sanofi-Aventis)
EC50 (μg/mL)	0.15	2.3	1.0
Maximum killing (%)	90	20	15

*MOR202 clone MOR03087; ¹:surrogate mAb produced in HEK cells, generated using VH and VL sequences as published PCT patent applications WO2012/041800 (MOR03087) and WO2008/047242 (38SB19); ²:38SB19



CD38 Landscape: Direct In-House Pre-Clinical Comparison with Surrogates of Competitor Antibodies

		Daratumumab (Genmab)	MOR202 ¹ (MorphoSys)	isatuximab ^{1, 2} (Sanofi-Aventis)	AB79 (Millennium/Takeda)
	Origin	Human	Human	Chimeric	Human
	Development phase	Phase III	Phase I/IIa	Phase I/II	Pre-clinical
	Binding ³	+++	++	+++	+++
	ADCC (max lysis) ³	++	++	++	++
	CDC (max lysis) ³	+++	+	+	++
Mechanism	Phagocytosis ^{3, 4}	+++	++	nd	+++
of Action	Ecto-enzyme function	+	-	+++	+
	Direct PCD 5, 6	-	-	++	-
	PCD after cross- linking ^{5, 6}	+++	+++	+++	+++


*MOR202 clone MOR03087; ¹:surrogate mAb produced in HEK cells, generated using VH and VL sequences as published in PCT applications WO2012/041800 (MOR03087) and WO2008/047242 (38SB19); ²:38SB19; ³:Daudi cells; ⁴:based on EC50 data, ⁵:Ramos cells ⁶: PCD: Programmed cell death, measured by Annexin V positivity and caspase-3 activation. nd = not determined




Daratumumab Beyond Multiple Myeloma Pre-clinical Activity in DLBCL & ALL

Effect daratumumab on tumor growth in patient-derived DLBCL model

Effect daratumumab with or without vincristine in ALL xenograft model






Genmab

Janssen Daratumumab Clinical Trials in Multiple Myeloma: Smoldering

NCT 02316106 (SMM2001 Centaurus) Enrolling Now: 120 Est. Pts




1 Cycle = 8 Weeks

Primary Endpoints: CR & Time to Progression to Symptomatic Multiple Myeloma



Janssen Daratumumab Clinical Trials in Multiple Myeloma: Frontline Non-Transplant

NCT 02195479 (MMY3007 Alcyone) Enrolling Now: 700 Est. Pts




1 Cycle = 28 Days

Primary Endpoint: PFS


^TGenmab Janssen Daratumumab Clinical Trials in Multiple Myeloma: Frontline Transplant

NCT 02541383 (MMY3006 Cassiopeia) Enrolling Now: 1,080 Est. Pts: Part 1




Janssen Daratumumab Clinical Trials in Multiple Myeloma: Relapsed or Refractory

NCT 02076009 (MMY3003 Pollux) Enrollment Complete: 570 Est. Pts




NCT 02136134 (MMY3004 Castor) Enrollment Complete: 480 Est. Pts



^{*Genmab} Janssen Daratumumab Clinical Trials in Multiple Myeloma: Relapsed or Refractory: Subcutaneous


NCT 02519452 (MMY1004) Enrolling Now: 128 Est. Pts Part 1



Primary Endpoint: Serum Trough Concentrations, Safety 1 Cycle = 28 Days

^{*Genmab} Janssen Daratumumab Clinical Trials in Multiple Myeloma: Relapsed or Refractory: Subcutaneous con't

NCT 02519452 (MMY1004) Not Yet Open for Enrollment: 128 Est. Pts Part 2




Primary Endpoint: Serum Trough Concentrations, Safety

1 Cycle = 28 Days



Ofatumumab: Planned & Ongoing Trials



Note: The indications above are unapproved

*Al rights to be acquired by Novartis



2014 & 2015 Ofatumumab Data

Ofatumumab maintenance prolongs PFS in relapsed CLL

- Population
 - Pts in CR or PR after 2nd & 3rd line treatment for CLL
 - Ofatumumab vs Observation
- Key Safety Data
 - Grade 3 & 4 AEs
 - Ofatumumab 25%
 - Observation 17%
- Key Efficacy Data
- PFS
 - Ofatumumab 28.6 months
- Observation 15.2 months
- Conclusion
- Ofatumumab maintenance provided significant clinical benefit for pts with relapsed CLL
- Well-tolerated with no unexpected toxicities


Ofatumumab + fludarabine + cyclophosphamide met primary endpoint of improved PFS in Relapsed CLL

- Population
- Pts with relapsed CLL
- Ofatumumab + fludarabine + cyclophosphamide vs fludarabine + cyclophosphamide
- Key Safety Data
- Consistent with other trials of ofatumumab
- No new safety signals observed
- Key Efficacy Data
- PFS
 - OFC 28.9 months
 - FC 18.8 months
- ORR
 - •84% OFC
 - •68% FC

Ofatumumab + Idelalisib in Previously Treated CLL

Population	Key safety data	Key efficacy data	Conclusion
 Relapsed CLL within 24 month after last therapy Median 3 prior lines of therapy Ofatumumab + idelalisib vs ofatumumab in 2:1 randomization Open label trial 	 Diarrhea/colitis 20%, pneumonia 12.7%, febrile neutropenia 11.6% Safety manageable with a profile similar to previously observed in CLL 	 Ofatumumab +idelalisib ORR 75.3% Median PFS 16.3 m Median OS 20.9 m Ofatumumab ORR 18% Median PFS 8 m Median OS 19.4 m 	 Met primary endpoint Combination of ofatumumab and idelalisib safe and feasible

Ofatumumab Potential to Combine with Tyrosine Kinase Inhibitors




Sources:


Da Roit et al. "Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy." Abstract. EHA 2014

Jaglowski et al. "A Phase Ib/II study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) and related diseases." ASCO 2014

HuMax-TF-ADC in Patients with Solid Tumors Best Percent Reduction from Baseline




Footnote: as per RECIST 1.1 (green), PSA (CRPC patients only, yellow), CA125 (ovarian cancer patients only, purple).




Genmab

Pre-study (August 2014)



Post therapy (May 2015)





*Sept 2015 Aduro BioTech, Inc. announced definitive agreement to acquire BioNovion

Genmab

Immuno-Oncology Turning Cancer into a Chronic Condition

Innovating cancer treatment


- · Activate the patient's own immune system to fight cancer
- Long duration of response
- Potential game changer
 - >\$50B market

Many immune checkpoint targets

· Combinations may improve survival outcome

DuoBody technology

- Robust & versatile BsAb platform
- Ideal for:
 - Screening multiple combinations in final therapeutic format
 - Combined targeting immune check point
- Partnerships with BioNovion and BioNTech





Immuno-Oncology Genmab as Key Player: Two Commercial Deals

BioNovion*

- Expansion of previous research collaboration
- Co-development agreement
- Bispecific antibodies to immuno-oncology targets to be created with DuoBody technology

BioNTech

- Co-development and commercialization agreement
- Collaboration will focus on multiple product candidates in field of immuno-oncology
- BioNTech provides antibody panels



Better Antibodies By Design

